Association of pretreatment amlodipine and outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Document Type : original articles

Authors

1 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Student Research Committee, Islamic Azad University of Tabriz, Iran

Abstract

Objectives: The current study is a retrospective cross-sectional study that reviewed 497 patients with an ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Demographic data including age, gender, history of Hypertension (HTN), diabetes mellitus, and smoking and data related to the use of Amlodipine, pic of cardiac troponin I (cardiac enzyme), ejection fraction (EF), arrhythmia at the admission, and death after PCI extracted from the previous file. The patients were divided into two groups, the first group with a history of taking amlodipine and the second group without a history of taking amlodipine. SPSS version 26 was used for data analysis. T-tests, chi-square, and Fisher's exact were used to test the relationship between variables.

Methods: In this retrospective cross-sectional study, the medical records of 497 patients with STEMI who underwent PCI were reviewed. The data were age, gender, previous use of Amlodipine, pic of cardiac troponin I (CINI), (EF), arrhythmia at the admission, history of HTN, Diabetes mellitus and smoking, and death after PCI. Then patients were divided into two groups with (group 1) or without (group 2) a history of Amlodipine use. Student t-test, chi-square test, and the Fisher exact test were applied to investigate the associations between variables using the SPSS version 26.

Results: Out of 497 patients included, 81.3% were males with a mean age of 58.7±12.02 years, and 22.7% had a history of taking amlodipine. Patients in group 2 showed more death and MI than group 1 (OR = 1.32 [95% CI, 1.25-1.39], P=0.002) and (OR=3.93 [95% CI, 2.24-6.87], P<0.001). There were no differences between the two groups in terms of age, sex, cTnI, EF, rate of arrhythmia, the pattern of vascular involvement, kind of vascular involvement, and occlusion location (P= 0.6, 0.9, 0.09, 0.1, 0.3, 0.28, 0.29 and 0.8, respectively).

Conclusions: Amlodipine administered before MI significantly reduced the mortality rate after PCI compared to patients not taking amlodipine. The result can be attributed to the antioxidant effect, limiting the consequences of injury around reperfusion.

Keywords

References

1.Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25): 2982-3021.
2.Mills KT, Stefanescu A, He J.The Global epidemiology of hypertension. Nat Rev Nephrol .2020; 16(4): 223-237.
3.Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-saharan africa: burden, risk and interventions. Intern Emerg Med. 2016; 11(3): 299-305.
4.Ataklte F, Erqou S, Kaptoge S, et al. Burden of undiagnosed hypertension in sub-saharan africa: a systematic review and meta-analysis. Hypertension. 2015; 65(2): 291-8.
5.Bundy JD, He J. Hypertension and related cardiovascular disease burden in china. Ann Glob Health. 2016; 82(2): 227-33.
6.St-Onge M, Dubé P-A, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014; 52(9): 926-44.
7.Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol. 2017; 8: 286.
8.Wright JM, Musini VM, Gill R. First‐line drugs for hypertension. Cochrane Database Syst Rev. 2018; 4(4): CD001841.
9.Tocci G, Battistoni A, Passerini J, et al. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther. 2015; 20(2): 121-30.
10.Maor E, Eleid MF, Gulati R, et al. Current and future use of robotic devices to perform percutaneous coronary interventions: A Review. J Am Heart Assoc. 2017; 6(7): e006239.
11.Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.  Eur Heart J. 2005; 26(8): 804-47.
12.Sheraz MA, Ahsan SF, Khan MF, et al. Formulations of amlodipine: a review. J Pharm (Cairo).2016; 2016 :8961621.
13.Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients. J Hypertens. 2009; 27(6): 1136-51.
14.Nishigaki K, Inoue Y, Yamanouchi Y, et al. Prognostic effects of Calcium Channel blockers in patients with vasospastic angina–a meta-analysis. Circ J. 2010 ;74(9):1943-50.
15.Dunlap ED, Matlib MA, Millard RW. Protection of regional mechanics and mitochondrial oxidative phosphorylation by amlodipine in transiently ischemic myocardium. Am J Cardiol. 1989;64(17):841-911.
16.L H Opie. Reperfusion injury and its pharmacologic modification. Circulation. 1989;80(4):1049-62.
17.Jørgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the coronary angioPlasty amlodipine REStenosis study (CAPARES). J Am Coll Cardiol. 2000;35(3):592-9.
18.Dens JA, Desmet WJ, Coussement P, et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Nisoldipine in coronary artery disease in Leuven. Am J Cardiol. 2001;87(1):28-33.
19.O'Keefe Jr JH, Giorgi LV, Hartzler GO, et al. Effects of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol. 1991;67(5):373-6.
20.Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol. 1987;59(3):84B-94B.
21.Masoumi S, Separham A, Parizad R, et al. Dual Left Anterior Descending Artery: Clinical Overview and Interventional Management. J Tehran Heart Cent. 2023;18(2):146–50.
22.Parsons RW, Hung J, Hanemaaijer I, et al. Prior calcium channel blockade and short-term survival following acute myocardial infarction. Cardiovasc Drugs Ther. 2001;15(6):487-92.
23.Hagar JM, Newman LG, Kloner RA. Effects of amlodipine on myocardial infarction, infarct expansion, and ventricular geometry in the rat. Am Heart J. 1992;124(3):571-80.
24.Jørgensen B, Thaulow E. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J. 2003;145(6):1030-5.
25.Gulmez O, Atar I, Ozin B, et al. The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions. Vasc Health Risk Manag. 2008;4(6):1417 -22.
26.Sandmann S, Claas R, Cleutjens JP, et al. Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats. J Cardiovasc Pharmacol. 2001;37(1):64-77.
27.Ashraf H, Soltani D, Sobh-Rakhshankhah A, et al.Visfatin as marker of isolated coronary artery ectasia and its severity. Cytokine. 2019;113:216–20.
28.Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1985;109(5):926-31.
Cardiovascular Biomedicine
Volume 3, Issue 1
August 2023
Pages 1-8

Files

History

  • Receive Date: 10 January 2022
  • Revise Date: 07 August 2023
  • Accept Date: 19 August 2023
  • First Publish Date: 22 August 2023

Share

How to cite

Statistics